Posted by Michael Wonder on 10 Aug 2019
ICER to assess treatments for sickle cell disease
9 August 2019 - Report will be subject of New England CEPAC meeting in March 2020; open Input now being accepted until 27 August 2019.
The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of crizanlizumab (Novartis) and voxelotor (Global Blood Therapeutics) for the treatment of sickle cell disease. Crizanlizumab, a P-selectin inhibitor, is currently under FDA priority review with an anticipated decision expected in the first half of 2020. Global Blood Therapeutics is planning to initiate and complete a rolling NDA for voxelotor, an HbS polymerization inhibitor, before the end of 2019.
ICER’s Evidence Report on sickle cell disease will be reviewed during a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in March 2020.
